Featured Product
This Week in Quality Digest Live
Health Care Features
Stephanie Ojeda
How addressing customer concerns benefits the entire quality process
Michael King
Augmenting and empowering life-science professionals
Meg Sinclair
100% real, 100% anonymized, 100% scary
Kristi McDermott
Technology and what the future requires for patients and providers to thrive
Alonso Diaz
Consulting the FDA’s Case for Quality program

More Features

Health Care News
Recognized among early adopters as a leading innovation for the life sciences industry
Study of intelligent noise reduction in pediatric study
Streamlines annual regulatory review for life sciences
The company is also facilitating donations to the cause
Mass spectromic analysis from iotaSciences
Showcasing the latest in digital transformation for validation professionals in life sciences
An expansion of its medical-device cybersecurity solution as independent services to all health systems
Purchase combines goals and complementary capabilities
Better compliance, outbreak forecasting, and prediction of pathogens such as listeria or salmonella

More News

Margaret A. Hamburg

Health Care

Visiting India: The Importance of Biomedical Research and Quality

Women’s roundtable in Mumbai meet with the FDA’s commissioner

Published: Thursday, March 6, 2014 - 16:04

As my busy and productive trip to India drew to a close, I had the opportunity for one final meeting and one last memory with a group of some of the country’s most extraordinary women. The occasion was a women’s roundtable in Mumbai, organized by the Confederation of Indian Industry (CII).

It brought together a diverse collection of female industry and academic leaders in India for a thought-provoking discussion and a wonderful chance to share perspectives with these accomplished women. We covered a wide range of important and timely topics and could have gone on for much longer had time allowed. We discussed the many challenges that professional women often face in today’s workplace, including efforts to achieve work-life balance and the importance of educating, motivating, mentoring, and empowering women at every stage of both their professional and personal development.

We also focused on a number of pressing issues in biomedical research, clinical trials, and the regulatory framework for food and drugs.

What was most striking about this remarkable group is the commitment each has made not only to support one another in their diverse professional endeavors, but also to work to improve the lives of people living in India and around the world.


FDA Commissioner Margaret A. Hamburg and members of the women’s roundtable in Mumbai, India.

Two themes emerged during our discussion: the importance of biomedical research in India, specifically clinical trial design and enrollment; and the importance of quality and the role these prominent leaders in the pharmaceutical and food-production sectors can play in communicating why quality matters.

The group expressed concern about the status of the clinical trial system in India. Many Indians have been wary of the way clinical trials have been conducted and how trial participants are chosen and informed. India has been in the midst of a significant reexamination of its clinical trial infrastructure and the legal, regulatory, ethical, and scientific requirements necessary for future research.

Certainly, we understand the importance of a vibrant, reliable, and transparent clinical trials system. The information the FDA receives and reviews from clinical trials conducted in the United States and abroad is an essential part of the agency’s decision making for all new and existing drugs. Without it, we wouldn’t have important information such as how a drug works, whether it’s reasonably safe for patients, and how the human body metabolizes the drug. Additionally, clinical trials may represent a vital mechanism to access an investigational drug for patients living with serious and life-threatening diseases.

Over the years, the FDA has worked closely with academia, industry, and the advocacy community to improve transparency around the design and conduct of the clinical trials used to generate data for medical product review and approval. The agency has been working with the healthcare and research community to improve clinical trial subjects’ understanding of what it means to participate in a clinical trial, as well as the specifics of the trial in which they are considering enrollment.

Because the information we learn from clinical trials has the potential to benefit people living around the world—and the trials may be conducted in a wide range of countries—it’s important that government officials, industry, the research community, and patient organizations work together to ensure appropriate human subject protection, rigorous clinical trial design, and needed healthcare. We look forward to continuing our discussions with government, industry, and academia on these important topics.

Quality was a recurring theme during my visit to India. I was pleased that the women who participated in the roundtable were as committed to quality as I am. As leaders in their industries and academic institutions, they are uniquely positioned to help reinforce the message that quality matters and to educate the next generation of leaders in their respective industries and organizations about the importance of building quality into everything they do.

And I was delighted that the group appreciated how smart regulation can help shape, support, and strengthen the product development and manufacturing processes that can help ensure continuous quality. In the words of moderator Swati Piramal, one of the highest ranking and most eminent leaders in Indian pharma today, “Good regulators make good companies.” And that combination can lead to better, safer, and higher-quality products—which benefits the health of people in both our nations and around the world.

Discuss

About The Author

Margaret A. Hamburg’s picture

Margaret A. Hamburg

Margaret A. Hamburg, M.D., is the commissioner of the U.S. Food and Drug Administration (FDA). The second woman to be nominated for this position, she is an experienced medical doctor, scientist, and public health executive. As the top official of the FDA, Hamburg is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health.